Corrigendum to “Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission” [Neuropharmacology 62 (2012) 765–774](S0028390811003649)(10.1016/j.neuropharm.2011.08.031);Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission

Neuropharmacology

Volumn 62, Issue 2, 2012, Pages 765-774

  Tanahashi, Shunsuke ^a   Yamamura, Satoshi ^a   Nakagawa, Masanori ^a   Motomura, Eishi ^a   Okada, Motohiro ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Aripiprazole; Dopamine; GABA; Microdialysis; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; SEROTONIN 1A RECEPTOR;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SEROTONINERGIC TRANSMISSION; VENTRAL TEGMENTUM;

EID: 84855979527     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2018.11.001     Document Type: Erratum

References (50)

1. A. Adell, and F. Artigas The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems Neurosci. Biobehav. Rev. 28 2004 415 431
2. S.P. Alexander, A. Mathie, and J.A. Peters Guide to receptors and channels (GRAC), 4th edition Br. J. Pharmacol. 158 Suppl. 1 2009 S1 254
3. T. Amano, H. Matsubayashi, T. Momiyama, K. Ishihara, N. Todo, and M. Sasa Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens Prog. Neuropsychopharmacol. Biol. Psychiatry 19 1995 105 116
4. M. Amargos-Bosch, A. Bortolozzi, M.V. Puig, J. Serrats, A. Adell, P. Celada, M. Toth, G. Mengod, and F. Artigas Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex Cereb. Cortex 14 2004 281 299
5. M.B. Assie, V. Ravailhe, V. Faucillon, and A. Newman-Tancredi Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain J. Pharmacol. Exp. Ther. 315 2005 265 272
6. S. Aznar, Z. Qian, R. Shah, B. Rahbek, and G.M. Knudsen The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain Brain Res. 959 2003 58 67
7. R.M. Berman, R.N. Marcus, R. Swanink, R.D. McQuade, W.H. Carson, P.K. Corey-Lisle, and A. Khan The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 68 2007 843 853
8. A. Bortolozzi, L. Diaz-Mataix, M. Toth, P. Celada, and F. Artigas In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain Psychopharmacology (Berl.) 191 2007 745 758
9. A. Breier Cognitive deficit in schizophrenia and its neurochemical basis Br. J. Psychiatry Suppl. 1999 16 18
10. K.D. Burris, T.F. Molski, C. Xu, E. Ryan, K. Tottori, T. Kikuchi, F.D. Yocca, and P.B. Molinoff Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J. Pharmacol. Exp. Ther. 302 2002 381 389
11. F.P. Bymaster, K. Rasmussen, D.O. Calligaro, D.L. Nelson, N.W. DeLapp, D.T. Wong, and N.A. Moore In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug J. Clin. Psychiatry 58 Suppl. 10 1997 28 36
12. A. Carlsson, N. Waters, S. Holm-Waters, J. Tedroff, M. Nilsson, and M.L. Carlsson Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence Annu. Rev. Pharmacol. Toxicol. 41 2001 237 260
13. N.H. Chen, and M.E. Reith Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin J. Neurochem. 64 1995 1585 1597
14. J.M. Cossery, H. Gozlan, U. Spampinato, C. Perdicakis, G. Guillaumet, L. Pichat, and M. Hamon The selective labelling of central 5-HT1A receptor binding sites by [3H]5-methoxy-3-(di-n-propylamino)chroman Eur. J. Pharmacol. 140 1987 143 155
15. A.J. Cutler, R.N. Marcus, S.A. Hardy, A. O'Donnell, W.H. Carson, and R.D. McQuade The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia CNS Spectr. 11 2006 691 702 (quiz 719)
16. G.L. Gessa, P. Devoto, M. Diana, G. Flore, M. Melis, and M. Pistis Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex Neuropsychopharmacology 22 2000 642 649
17. B. Green Focus on aripiprazole Curr. Med. Res. Opin. 20 2004 207 213
18. G. Grunder, A. Carlsson, and D.F. Wong Mechanism of new antipsychotic medications: occupancy is not just antagonism Arch. Gen. Psychiatry 60 2003 974 977
19. P. Hertel Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action Synapse 60 2006 543 552
20. J. Ichikawa, and H.Y. Meltzer R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum J. Pharmacol. Exp. Ther. 291 1999 1227 1232
21. S. Ikemoto Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex Brain Res. Rev. 56 2007 27 78
22. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225
23. S. Jordan, V. Koprivica, R. Chen, K. Tottori, T. Kikuchi, and C.A. Altar The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor Eur. J. Pharmacol. 441 2002 137 140
24. S. Jordan, V. Koprivica, R. Dunn, K. Tottori, T. Kikuchi, and C.A. Altar In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function Eur. J. Pharmacol. 483 2004 45 53
25. R.M. Kessler, J.R. Votaw, T. de Paulis, D.R. Bingham, M.S. Ansari, N.S. Mason, G. Holburn, D.E. Schmidt, D.B. Votaw, and R.G. Manning Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors Synapse 15 1993 169 176
26. Z. Li, J. Ichikawa, J. Dai, and H.Y. Meltzer Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain Eur. J. Pharmacol. 493 2004 75 83
27. H. Luna-Munguia, L. Manuel-Apolinar, L. Rocha, and A. Meneses 5-HT1A receptor expression during memory formation Psychopharmacology (Berl.) 181 2005 309 318
28. S. Mace, and D. Taylor Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder CNS Drugs 23 2009 773 780
29. R. Martin-Ruiz, M.V. Puig, P. Celada, D.A. Shapiro, B.L. Roth, G. Mengod, and F. Artigas Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism J. Neurosci. 21 2001 9856 9866
30. T. Matsuda, Y.H. Seong, H. Aono, T. Kanda, A. Baba, K. Saito, A. Tobe, and H. Iwata Agonist activity of a novel compound, 1-[3-(3,4- methylenedioxyphenoxy)propyl]-4-phenyl piperazine (BP-554), at central 5-HT1A receptors Eur. J. Pharmacol. 170 1989 75 82
31. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1159 1172
32. K. Ohoyama, S. Yamamura, T. Hamaguchi, M. Nakagawa, E. Motomura, T. Shiroyama, H. Tanii, and M. Okada Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex Eur. J. Pharmacol. 653 2011 47 57
33. M. Okada, D.J. Nutt, T. Murakami, G. Zhu, A. Kamata, Y. Kawata, and S. Kaneko Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release J. Neurosci. 21 2001 628 640
34. M. Okada, G. Zhu, S. Yoshida, S. Hirose, and S. Kaneko Protein kinase associated with gating and closing transmission mechanisms in temporoammonic pathway Neuropharmacology 47 2004 485 504
35. V.G. Olson, and E.J. Nestler Topographical organization of GABAergic neurons within the ventral tegmental area of the rat Synapse 61 2007 87 95
36. V.G. Olson, C.P. Zabetian, C.A. Bolanos, S. Edwards, M. Barrot, A.J. Eisch, T. Hughes, D.W. Self, R.L. Neve, and E.J. Nestler Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area J. Neurosci. 25 2005 5553 5562
37. G. Paxinos, and C. Watson The Rat Brain in Stereotoxic Coordinates 1998 Academic Press San Dieg.
38. G. Sachs, R. Sanchez, R. Marcus, E. Stock, R. McQuade, W. Carson, N. Abou-Gharbia, C. Impellizzeri, S. Kaplita, L. Rollin, and T. Iwamoto Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study J. Psychopharmacol. 20 2006 536 546
39. N. Santana, A. Bortolozzi, J. Serrats, G. Mengod, and F. Artigas Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex Cereb. Cortex 14 2004 1100 1109
40. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.X. Liu, D.R. Sibley, B.L. Roth, and R. Mailman Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
41. A. Sparshatt, D. Taylor, M.X. Patel, and S. Kapur A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring J. Clin. Psychiatry 2010 1447 1456
42. L.W. Swanson The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat Brain Res. Bull. 9 1982 321 353
43. Y. Tadori, T. Miwa, K. Tottori, K.D. Burris, A. Stark, T. Mori, and T. Kikuchi Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic Eur. J. Pharmacol. 515 2005 10 19
44. R. Tandon, R.N. Marcus, E.G. Stock, L.C. Riera, D. Kostic, M. Pans, R.D. McQuade, M. Nyilas, T. Iwamoto, and D.T. Crandall A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) Schizophr. Res. 84 2006 77 89
45. S. Yamamura, K. Ohoyama, T. Hamaguchi, K. Kashimoto, M. Nakagawa, S. Kanehara, D. Suzuki, T. Matsumoto, E. Motomura, T. Shiroyama, and M. Okada Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex Psychopharmacology (Berl.) 206 2009 243 258
46. S. Yamamura, K. Ohoyama, T. Hamaguchi, M. Nakagawa, D. Suzuki, T. Matsumoto, E. Motomura, H. Tanii, T. Shiroyama, and M. Okada Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex Br. J. Pharmacol. 157 2009 656 665
47. F. Yokoi, G. Grunder, K. Biziere, M. Stephane, A.S. Dogan, R.F. Dannals, H. Ravert, A. Suri, S. Bramer, and D.F. Wong Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride Neuropsychopharmacology 27 2002 248 259
48. S. Yoshida, M. Okada, G. Zhu, and S. Kaneko Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor Neuropharmacology 52 2007 1538 1546
49. K. Yoshimoto, and W.J. McBride Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat Neurochem. Res. 17 1992 401 407
50. A. Zocchi, D. Fabbri, and C.A. Heidbreder Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex Neurosci. Lett. 387 2005 157 161